iCarTab is committed to the development of tumor immunotherapy technology, and has accumulated rich experience in the CAR-T/TCR-T technology field. At present, we have constructed CAR lentivirus packaging plasmids with multiple targets, covering current clinical research hotspots. On this basis, we can also provide one-stop antibody screening, verification, CAR-T construction, in vivo and in vitro pharmacodynamic verification and other services.